Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:

• Introduction (0:00)
• Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)
• Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)
• Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)
• Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)

CME information and select publications

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

• Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
• Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
• Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
• Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
• Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
• Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
• Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
• Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)

CME information and select publications

Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

• Introduction: ODAC — April 30, 2026 (00:00)
• Adjuvant CDK4/6 Inhibitors (13:03)
• Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)
• Premenopausal Patients (30:52)
• Duration of Adjuvant Endocrine Treatment (38:44)
• Genomic Predictors of Chemotherapy Benefit (47:19)
• Neoadjuvant Treatment (55:13)

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (2:07)
• Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
• Currently Available ADCs for Gynecologic Cancer Management (26:37)
• Currently Available ADCs for Lung Cancer Management (44:07)
• Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
• Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
• Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:

• Introduction (00:00)
• Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)
• Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)
• Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)
• Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)
• Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)
• Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)

CME information and select publications

Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics:

• Introduction: Where We Are; Where We’re Heading (0:00)
• First-Line Treatment of BRCA Wild-Type Disease (9:14)
• First-Line Treatment of BRCA-Mutant Disease (38:48)
• Novel Approaches (47:49)

CME information and select publications

Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics:

• Introduction (0:00)
• Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58)
• Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51)

CME information and select publications